title: Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
abstract: Objective To explore trends in demographics, comorbidities, anti-diabetic drug usage, and healthcare utilization costs in patients with newly-diagnosed type 2 diabetes mellitus (T2DM) using a large US claims database. Methods For the years 2007 and 2012, Truven Health Marketscan Research Databases were used to identify adults with newly-diagnosed T2DM and continuous 12-month enrollment with prescription benefits. Variables examined included patient demographics, comorbidities, inpatient utilization patterns, healthcare costs (inpatient and outpatient), drug costs, and diabetes drug claim patterns. Results Despite an increase in the overall database population between 2007-2012, the incidence of newly-diagnosed T2DM decreased from 1.1% (2007) to 0.65% (2012). Hyperlipidemia and hypertension were the most common comorbidities and increased in prevalence from 2007 to 2012. In 2007, 48.3% of newly-diagnosed T2DM patients had no claims for diabetes medications, compared with 36.2% of patients in 2012. The use of a single oral anti-diabetic drug (OAD) was the most common diabetes medication-related claim (46.2% of patients in 2007; 56.7% of patients in 2012). Among OAD monotherapy users, metformin was the most commonly used and increased from 2007 (74.7% of OAD monotherapy users) to 2012 (90.8%). Decreases were observed for sulfonylureas (14.1% to 6.2%) and thiazolidinediones (7.3% to 0.6%). Insulin, predominantly basal insulin, was used by 3.9% of patients in 2007 and 5.3% of patients in 2012. Mean total annual healthcare costs increased from $13,744 in 2007 to $15,175 in 2012, driven largely by outpatient services, although costs in all individual categories of healthcare services (inpatient and outpatient) increased. Conversely, total drug costs per patient were lower in 2012 compared with 2007. Conclusions Despite a drop in the rate of newly-diagnosed T2DM from 2007 to 2012 in the US, increased total medical costs and comorbidities per individual patient suggest that the clinical and economic trends for T2DM are not declining.
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: W
authors: W
authors: Weng
authors: b Truven Health Analytics , Cambridge , MA , USA.
authors: Y
authors: Y
authors: Liang
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: E S
authors: ES
authors: Kimball
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: T
authors: T
authors: Hobbs
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: S
authors: S
authors: Kong
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: B
authors: B
authors: Sakurada
authors: a Novo Nordisk Inc. , Plainsboro , NJ , USA ;
authors: J
authors: J
authors: Bouchard
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D004363:Drug Utilization / Q000191:economics* / Q000706:statistics & numerical data*; D005260:Female; D005102:Health Expenditures; D006296:Health Services / Q000706:statistics & numerical data; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000145:classification / Q000191:economics* / Q000627:therapeutic use*; D007345:Insurance Claim Review; D008297:Male; D008875:Middle Aged; D017678:Sex Distribution; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents
keywords: Basal insulin; Comorbidities; Healthcare costs; Oral anti-diabetic medicine; Treatment patterns